Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 2/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2307682 | 1.00 | LTA4H (0.55) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| SCHEMBL27878054 | 1.00 | LTA4H (0.55) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| Hydrochloric Acid SCHEMBL29264506 | 0.98 | LTA4H (0.54) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| SCHEMBL15989154 | 0.91 | GRIK1 (0.55) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| SCHEMBL7077555 | 0.91 | GRIK1 (0.55) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| SCHEMBL15989178 | 0.90 | LTA4H (0.52) | LTA4HCTSSCTSKSLC7A5GRIK1 | |
| SCHEMBL8555976 | 0.87 | SMN1; SMN2 (0.49) | LTA4HGRIK1SMN1; SMN2ANPEPERAP1 | |
| SCHEMBL15989057 | 0.87 | SMN1; SMN2 (0.46) | LTA4HGRIK1SMN1; SMN2ANPEPERAP1 | |
| SCHEMBL29831840 | 0.86 | CYP3A4 (0.43) | LTA4HCTSSCTSKSLC7A5LNPEP | |
| SCHEMBL5707507 | 0.85 | METAP2 (0.58) | LTA4HCTSSCTSKITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024637-B | Method for preparing carfilzomib by taking water-soluble alkynylamide as condensing agent | 江西师范大学 | 2023-05-16 | — | — | CN | claimed |
| CN-113024637-A | Method for preparing carfilzomib by using water-soluble alkynylamide as condensing agent | 江西师范大学 | 2021-06-25 | — | — | CN | claimed |
| CN-113024637-B | Method for preparing carfilzomib by taking water-soluble alkynylamide as condensing agent | 江西师范大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-113024637-B | Method for preparing carfilzomib by taking water-soluble alkynylamide as condensing agent | 江西师范大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-113024637-A | Method for preparing carfilzomib by using water-soluble alkynylamide as condensing agent | 江西师范大学 | 2021-06-25 | — | — | CN | disclosed |
| CN-113024637-A | Method for preparing carfilzomib by using water-soluble alkynylamide as condensing agent | 江西师范大学 | 2021-06-25 | — | — | CN | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| CN-102766058-A | Synthetic method of alpha-amino acid with photolytic activity | CHINESE ACAD INST CHEMISTRY | 2012-11-07 | — | — | CN | disclosed |
| CN-102675135-A | Method for synthesizing alpha-amino-acid ester | CHINESE ACAD INST CHEMISTRY | 2012-09-19 | — | — | CN | disclosed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
| US-6403055-B1 | CARBOXYLATED POLYAMINE COMPOUND | DIBRA S.P.A. (IT) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | LTA4H 98/4885CTSS 492/4885CTSK 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.